Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study

Basit Öğe Kaydı
dc.authorid0000-0002-2049-1316
dc.contributor.authorKara Polat, Asude
dc.contributor.authorTopal, İlteriş Oğuz
dc.contributor.authorAslan Kayıran, Melek
dc.contributor.authorKoku Aksu, Ayşe Esra
dc.contributor.authorAytekin, Sema
dc.contributor.authorTopaloğlu Demir, Filiz
dc.contributor.authorÖzkök Akbulut, Tuğba
dc.contributor.authorKıvanç Altunay, İlknur
dc.contributor.authorÖzkur, Ezgi
dc.contributor.authorKaradağ, Ayşe Serap
dc.date.accessioned2021-10-12T07:08:46Z
dc.date.available2021-10-12T07:08:46Z
dc.date.issued2021
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıklar Ana Bilim Dalı
dc.description.abstractAcitretin is a nonimmunosuppresive systemic agent used in the treatment of psoriasis. Despite its frequent use, research on drug survival and adverse effects is limited. This study aims to evaluate drug survival, factors associated with survival, and adverse effects. Database of the six tertiary referral center for psoriasis patients treated with acitretin between November 2014 and April 2020 were retrospectively analyzed. Demographics of patients, adverse effects, and also drug survival were analyzed. Of 412 patients, 61.2% were male, and 38.8% were female. Common clinical adverse effects were cheilitis (71.4%), dry skin (62.5%), and palmoplantar skin peeling (37.2%). High triglyceride and high total cholesterol levels were observed in 50.0% and 49.5% of patients, respectively. Median survival time (95% confidence interval [CI]) was 18 (13.6-22.4) months. Statistically significant risk factors affecting drug discontinuation were having psoriatic arthritis, age under 65, and receiving previous systemic treatment. Drug survival rates were 56.6%, 25.9%, and 19.8% at 1, 5, and 8 years, respectively. Although mucocutaneous adverse effects of the acitretin were quite frequent, severe, life-treatining ones were infrequent. This old, relatively inexpensive and safe treatment remains a good alternative for the treatment of psoriasis.
dc.identifier.citationKara Polat, A., Topal, İ. O., Aslan Kayıran, M., Koku Aksu, A. E., Aytekin, S., Topaloğlu Demir, F. ... Karadağ, A. S. (2021). Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study. Dermatologic Therapy, 34(2). https://dx.doi.org/10.1111/dth.14834
dc.identifier.doi10.1111/dth.14834
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.issue2
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.1111/dth.14834
dc.identifier.urihttps://hdl.handle.net/20.500.12511/8425
dc.identifier.volume34
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofDermatologic Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectAcitretin
dc.subjectAdverse Effect
dc.subjectDrug Survival
dc.subjectPsoriasis
dc.titleDrug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Topaloglu-Filiz-2021.pdf
Boyut:
1.43 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu